PBT2

Last updated
PBT2
PBT2.svg
Names
Preferred IUPAC name
5,7-Dichloro-2-[(dimethylamino)methyl]quinolin-8-ol
Identifiers
3D model (JSmol)
ChemSpider
PubChem CID
UNII
  • InChI=1S/C12H12Cl2N2O/c1-16(2)6-7-3-4-8-9(13)5-10(14)12(17)11(8)15-7/h3-5,17H,6H2,1-2H3
    Key: YZPOQCQXOSEMAZ-UHFFFAOYSA-N
  • CN(C)CC1=NC2=C(C=C1)C(=CC(=C2O)Cl)Cl
Properties
C12H12Cl2N2O
Molar mass 271.14 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

PBT2 is a safe-for-human-use Zinc ionophore [1] and an experimental drug candidate. It is a second-generation 8-hydroxyquinoline analog [2] intended to be a successor to clioquinol and a potential treatment of Alzheimer's disease [3] and Huntington's disease.

Contents

Clinical trials

PBT2 was the subject of three phase II clinical trials for Alzheimer's disease ('EURO'), [4] 'IMAGINE' & 'IMAGINE EXTENSION') and one for Huntington's disease ('REACH2HD') [5] trial.

The cognition efficacy results for Alzheimer's disease were mixed. The EURO trial showed some improvements in cognitive functions, in particular executive function domains, while the IMAGINE study did not. [6] [7] [8] [9] Although there is no evidence that PBT2 is of any benefit in Alzheimer's dementia, [10] the number of subjects treated with PBT2 for AD in Phase II placebo controlled trials (N~76) is limited and the trials were not powered to detect cognitive outcomes. In the Phase II PBT2 trial in Huntington disease, whilst the overall cognitive composite measured was not improved, an executive function domain within the composite was significantly improved. [6] [7]

Phase II studies in AD

PBT2-201 (EURO) was a 12-week randomized, double-blind, placebo-controlled, parallel three-group study (Phase II) to assess the safety, tolerability and efficacy of two dose levels of PBT2 to slow progression of disease in patients with early AD. Seventy-eight (78) patients were enrolled and all were evaluated for safety and efficacy. PBT2 treatment of 50 and 250 mg a day was well tolerated in patients with AD during 12 weeks of treatment, with some evidence that the PBT2 250 mg/day dose can modulate certain biomarkers associated with AD, notably a significant decrease in CSF Abeta levels, and improvement in aspects of cognitive function as measured by the Executive Function composite z score and the individual Trails Making Test (TMT) Part B and the Category Fluency tests. [8]

PBT2-204 (IMAGINE) was a 12-month brain amyloid imaging study in which patients with mild AD (n=42) were administered PBT2 250 mg or placebo. Forty-two (42) patients were enrolled and all were evaluated for safety and efficacy. PBT2 was shown to be safe and very well tolerated over the 52 weeks, with the adverse event profile equivalent between placebo and treated groups. There was no difference in brain amyloid levels between the PBT2- and placebo-treated groups as measured by PiB. [9]

PBT2-204-Ext (Extension) [11] Thirty-three (n=33) patients continued on 250 mg PBT2 in an open-label extension study and were evaluated for safety and efficacy, with n=27 patients completing the study. The safety findings indicate that longer-term treatment (up to 104 weeks) with PBT2 250 mg was well tolerated in patients with prodromal or mild AD. The safety findings from this study are consistent with those that would be expected in a population of elderly adults with prodromal or mild AD.

Phase II study in HD

PBT2-203 (Reach2HD) [5] was a 6-month safety, tolerability and efficacy study in HD. Patients with early to mid-stage HD (n=109) received PBT2 100 mg, PBT2 250 mg or placebo once daily. The primary objective of the study was to evaluate the safety and tolerability of two dose levels of PBT2 (100 mg and 250 mg, once daily) compared to Placebo after 26 weeks in participants with early to mid-stage HD. PBT2 was shown to be safe and well tolerated over the 26 weeks, with the adverse event profile equivalent between placebo and PBT2 groups.

The secondary objectives of the study focused on the specific symptoms or manifestations of HD. The primary efficacy objective of the study was to determine the effect of PBT2 on cognition as measured by a cognitive test battery consisting of Category Fluency Test, TMT Parts A and B, Map Search, Symbol Digit Modalities Test, Stroop Word Reading Test, Speeded Tapping Task and MoCA. The results of these assessments were used to calculate three composite z-scores of cognition – the Main Composite z-score, Exploratory Composite z-score and Executive Function z-score.

PBT2 showed signs of improving some aspects of cognitive function in the study. The 250 mg dose of PBT2, administered once daily, showed better and statistically significant efficacy over the 12-week treatment period compared to placebo for the Main Composite Cognition Score (p=0.020), Exploratory composite cognition z-score (p=0.016), Executive Function composite Z score (p=0.005) and TMT Part B (p<0.001), a cognitive assessment tool. At 26 weeks, TMT Part B was statistically significantly improved (p=0.042) and the Executive Function composite z score trending to improvement. In patients with early HD (Total Functional Capacity 11-13), the Executive Function composite z score was statistically significantly improved (p=0.038).

Overall the results indicate that larger trials are needed to fully assess the safety and efficacy profile of PBT2 in AD and HD. [10] [5]

Other applications

PBT2 has been studied for its potential use in the treatment of infections with multidrug-resistant bacteria. [12] [13] In combination with zinc, PBT2 has been shown to reverse antibiotic resistance for a number of clinically significant bacterial pathogens, including Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus (MRSA), group A Streptococcus (GAS), and vancomycin-resistant Enterococcus (VRE) both in vitro and in a mouse infection model. [1] [13]

See also

Related Research Articles

<span class="mw-page-title-main">Donepezil</span> Medication used for dementia

Donepezil, sold under the brand name Aricept among others, is a medication used to treat dementia of the Alzheimer's type. It appears to result in a small benefit in mental function and ability to function. Use, however, has not been shown to change the progression of the disease. Treatment should be stopped if no benefit is seen. It is taken by mouth or via a transdermal patch.

<span class="mw-page-title-main">Galantamine</span> Neurological medication

Galantamine is used for the treatment of cognitive decline in mild to moderate Alzheimer's disease and various other memory impairments. It is an alkaloid that has been isolated from the bulbs and flowers of Galanthus nivalis, Galanthus caucasicus, Galanthus woronowii, and some other members of the family Amaryllidaceae, such as Narcissus (daffodil), Leucojum aestivum (snowflake), and Lycoris including Lycoris radiata. It can also be produced synthetically.

<span class="mw-page-title-main">Tarenflurbil</span> Chemical compound

Tarenflurbil, Flurizan or R-flurbiprofen, is the single enantiomer of the racemate NSAID flurbiprofen. For several years, research and trials for the drug were conducted by Myriad Genetics, to investigate its potential as a treatment for Alzheimer's disease; that investigation concluded in June 2008 when the company announced it would discontinue development of the compound.

The Thrombolysis In Myocardial Infarction, or TIMI Study Group, is an Academic Research Organization (ARO) affiliated with Brigham and Women's Hospital and Harvard Medical School dedicated to advancing the knowledge and care of patients with cardiovascular disease. The TIMI Study Group provides robust expertise in the key aspects of a clinical trial, including academic leadership, global trial management, biostatistics, clinical event adjudication, safety desk, medical hotline, and core laboratories. The group has its headquarters in Boston, Massachusetts.

<span class="mw-page-title-main">Latrepirdine</span> Antihistamine drug

Latrepirdine is an antihistamine drug which has been used clinically in Russia since 1983.

<i>scyllo</i>-Inositol Chemical compound

scyllo-Inositol is one of the stereoisomers of inositol. It is also known as scyllitol, cocositol, quercinitol, and 1,3,5/2,4,6-hexahydroxycyclohexane. scyllo-Inositol is a naturally occurring plant sugar alcohol found most abundantly in the coconut palm.

<span class="mw-page-title-main">Tesofensine</span> Chemical compound

Tesofensine (NS2330) is a serotonin–noradrenaline–dopamine reuptake inhibitor from the phenyltropane family of drugs, which is being developed for the treatment of obesity. Tesofensine was originally developed by a Danish biotechnology company, NeuroSearch, who transferred the rights to Saniona in 2014.

<span class="mw-page-title-main">Semagacestat</span> Chemical compound

Semagacestat (LY-450139) was a candidate drug for a causal therapy against Alzheimer's disease. It was originally developed by Eli Lilly and Elan, and clinical trials were conducted by Eli Lilly. Phase III trials included over 3000 patients, but in August 2010, a disappointing interim analysis, in which semagacestat performed worse than the placebo, led to the trials being stopped.

Solanezumab is a monoclonal antibody being investigated by Eli Lilly as a neuroprotector for patients with Alzheimer's disease. The drug originally attracted extensive media coverage proclaiming it a breakthrough, but it has failed to show promise in Phase III trials.

Pridopidine is an orally administrated small molecule investigational drug. Pridopidine is a selective and potent Sigma-1 Receptor agonist. It is being developed by Prilenia Therapeutics and is currently in late-stage clinical development for Huntington’s disease (HD) and Amyotrophic Lateral Sclerosis (ALS).

<span class="mw-page-title-main">Rivastigmine</span> Chemical compound

Rivastigmine is a cholinesterase inhibitor used for the treatment of mild to moderate Alzheimer's disease. The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting.

Crenezumab is a fully humanized monoclonal antibody against human 1-40 and 1-42 beta amyloid, which is being investigated as a treatment of Alzheimer's disease. Crenezumab is highly homologous to solanezumab, another monoclonal antibody targeting amyloid-β peptides. In June 2022, the US National Institutes of Health announced that the drug failed as a medication for early-onset Alzheimer's disease following the results of a decade-long clinical trial.

<span class="mw-page-title-main">NSI-189</span> Chemical compound

NSI-189 is an experimental, potential antidepressant that was developed by Neuralstem, Inc. for the treatment for major depressive disorder (MDD), as well as for cognitive impairment and neurodegeneration.

<span class="mw-page-title-main">Filgotinib</span>

Filgotinib, sold under the brand name Jyseleca, is a medication used for the treatment of rheumatoid arthritis (RA). It was developed by the Belgian-Dutch biotech company Galapagos NV.

<span class="mw-page-title-main">Upadacitinib</span> Chemical compound (medication)

Upadacitinib, sold under the brand name Rinvoq, is a Janus kinase (JAK) inhibitor medication for the treatment of moderately to severely active rheumatoid arthritis and psoriatic arthritis in adults where methotrexate did not work well or could not be tolerated. It was approved for medical use in the United States and in the European Union in 2019, and was developed by the biotech company AbbVie. On January 14, 2022 Rinvoq received FDA approval for treating treatment refractory atopic dermatitis.

<span class="mw-page-title-main">Clive Ballard</span>

Clive Ballard is a British, world-leading expert in dementia. He is currently Professor of Age-Related Diseases at the University of Exeter and Interim Deputy Pro-Vice-Chancellor and Dean of the University of Exeter Medical School.

Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of Alzheimer's disease. Lecanemab is an amyloid beta-directed antibody. It is given via intravenous infusion.

<span class="mw-page-title-main">Phenserine</span> Chemical compound

Phenserine is a synthetic drug which has been investigated as a medication to treat Alzheimer's disease (AD), as the drug exhibits neuroprotective and neurotrophic effects.

Donanemab (USAN; development code LY3002813) is a biological drug in trial to treat early symptoms of Alzheimer's disease. There is no cure or treatment for Alzheimer’s disease. Donanemab has shown positive results in Eli Lilly and Co.’s first two trials. Donanemab was developed by the company Eli Lilly and Co, used in past and current trials as a possible source of treatment for the heterogeneous condition Alzheimer’s disease. Donanemab, also known as N3pG, is an antibody produced in mice that targets an abnormal protein, amyloid beta (Aβ), that is produced in the bone marrow. Whilst the cause of Alzheimer’s disease is still unknown, great advances in amyloid pathology have led to a relation between the quantity of Aβ peptides and the development of Alzheimer's disease. Aβ peptides are deposited in the brain and when in excess will bind together to create a protein plaque. Donanemab targets this protein plaque, clearing the excess protein which causes a burden in the brain.

Iclepertin is an investigational nootropic to enhance the cognition and functional capacity in schizophrenia developed by Boehringer Ingelheim. As of May 2020, it is in phase III of clinical trial under the code name CONNEX-3. BI 425809 is an inhibitor of glycine transporter 1 (Gly-T1) that in phase II improved cognition after 12 weeks in patients with schizophrenia. Doses of 10 mg and 25 mg showed the largest separation from placebo. If these encouraging results are confirmed in phase 3 trials, BI 425809 could provide an effective treatment for cognitive impairment associated with schizophrenia. Schizophrenia is characterized by abnormalities in glutamatergic pathways related to NMDA receptor hypofunction. Inhibition of GlyT1 on the presynaptic membrane or astrocytes is hypothesized to increase glycine levels within the synapse. The NMDA receptor function may be enhanced by increasing levels of its co-agonist, glycine, within the synaptic cleft, which may lead to improvements in cognitive function.

References

  1. 1 2 Bohlmann, Lisa; De Oliveira, David M. P.; El-Deeb, Ibrahim M.; Brazel, Erin B.; Harbison-Price, Nichaela; Ong, Cheryl-lynn Y.; Rivera-Hernandez, Tania; Ferguson, Scott A.; Cork, Amanda J.; Phan, Minh-Duy; Soderholm, Amelia T.; Davies, Mark R.; Nimmo, Graeme R.; Dougan, Gordon; Schembri, Mark A.; Cook, Gregory M.; McEwan, Alastair G.; von Itzstein, Mark; McDevitt, Christopher A.; Walker, Mark J.; Kline, Kimberly A. (11 December 2018). "Chemical Synergy between Ionophore PBT2 and Zinc Reverses Antibiotic Resistance". mBio. 9 (6). doi: 10.1128/mBio.02391-18 . PMC   6299484 . PMID   30538186.
  2. ↑ Adlard, Paul A.; Cherny, Robert A.; Finkelstein, David I.; Gautier, Elisabeth; Robb, Elysia; Cortes, Mikhalina; Volitakis, Irene; Liu, Xiang; et al. (2008). "Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs is Associated with Decreased Interstitial Aβ". Neuron. 59 (1): 43–55. doi: 10.1016/j.neuron.2008.06.018 . PMID   18614028.
  3. ↑ Duce, James A.; Tsatsanis, Andrew; Cater, Michael A.; James, Simon A.; Robb, Elysia; Wikhe, Krutika; Leong, Su Ling; Perez, Keyla; et al. (2010). "Iron-Export Ferroxidase Activity of β-Amyloid Precursor Protein is Inhibited by Zinc in Alzheimer's Disease". Cell. 142 (6): 857–67. doi:10.1016/j.cell.2010.08.014. PMC   2943017 . PMID   20817278.
  4. ↑ Lannfelt, L; et al. (2008). ""Safety, efficacy, andbiomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phaseIIa, double-blind, randomised, placebo-controlled trial"". Lancet Neurol. 7 (9): 779–786. doi:10.1016/s1474-4422(08)70167-4. PMID   18672400. S2CID   44765010.
  5. 1 2 3 Huntington Study Group Reach2HD Investigators (2015). "Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial". Lancet Neurol. 14 (1): 39–47. doi:10.1016/S1474-4422(14)70262-5. PMID   25467848. S2CID   7199604.
  6. 1 2 "Prana Biotech Plunges 76%; Drug Fails in Alzheimer Study"
  7. 1 2 "PBT2 Takes a Dive in Phase 2 Alzheimer's Trial"
  8. 1 2 Lannfelt, L; et al. (2008). "Safety, efficacy, andbiomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phaseIIa, double-blind, randomised, placebo-controlled trial". Lancet Neurol. 7 (9): 779–786. doi:10.1016/s1474-4422(08)70167-4. PMID   18672400. S2CID   44765010.
  9. 1 2 "Prana Biotechnology announces top line results of Phase 2 IMAGINE trial of PBT2 in Alzheimer's disease". March 31, 2014.
  10. 1 2 "There is no evidence that MPACs (PBT1 or PBT2) are of benefit in Alzheimer's dementia"
  11. ↑ "Prana Announces Safety Outcomes of Alzheimer's IMAGINE Extension Trial". June 30, 2015.
  12. ↑ University of Melbourne (January 12, 2022). "Breaking bacterial antibiotic resistance to rescue front-line drug treatments".
  13. 1 2 Brazel, Erin B.; Tan, Aimee; Neville, Stephanie L.; Iverson, Amy R.; Udagedara, Saumya R.; Cunningham, Bliss A.; Sikanyika, Mwilye; Oliveira, David M. P. De; Keller, Bernhard; Bohlmann, Lisa; El-Deeb, Ibrahim M. (2022-01-11). "Dysregulation of Streptococcus pneumoniae zinc homeostasis breaks ampicillin resistance in a pneumonia infection model". Cell Reports. 38 (2): 110202. doi: 10.1016/j.celrep.2021.110202 . ISSN   2211-1247. PMC   9084593 . PMID   35021083. S2CID   245890773.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.